$PBYI News
Last published 6d ago
- 6d agoPBYIPuma Biotechnology Third Quarter 2026 Results Call - PUMA BIOTECHNOLOGY INCEarnings Call TranscriptsGood afternoon. My name is Latonya and I will be your conference call operator today. At this time, all participants are in a listen-only mode. After the speaker's formal remarks, there will be a question and answer sess
- 6d agoPBYIPuma Biotechnology Third Quarter 2026 Results Call - PUMA BIOTECHNOLOGY INCEarnings Call TranscriptsGood afternoon. My name is Latonya and I will be your conference call operator today. At this time, all participants are in a listen-only mode. After the speaker's formal remarks, there will be a question and answer sess
- 6d agoPBYIPUMA BIOTECHNOLOGY, INC. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoPBYIPuma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial ResultsBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, November 5, 2026, following the release of its third quarter 2026 financial
- 1mo agoPBYIPuma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on October 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit
- 1mo agoPBYIPuma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung CancerBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA®-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with
- 2mo agoPBYIPuma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment ConferenceBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 3:30 p.m. ET on Monday,
- 2mo agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on September 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit
- 3mo agoPBYIPuma Biotechnology Reports Second Quarter 2026 Financial ResultsBusiness WireRaising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June
- 3mo agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on August 3, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit
- 3mo agoPBYIPuma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial ResultsBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 6, 2026, following the release of its second quarter 2026 financial
- 4mo agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on July 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards
- 5mo agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards
- 6mo agoPBYIPuma Biotechnology Reports First Quarter 2026 Financial ResultsBusiness WireRaising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31,
- 6mo agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards
- 6mo agoPBYIPuma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial ResultsBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter 2026 financial
- 7mo agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards
- 8mo agoNKEPBYIADS-DEPUM-DESportswear giant Adidas drops 8% after profit guidance disappointsCNBCAdidas shares have fallen about 43% over the past year as investors remain skeptical about the growth prospects of the global sportswear industry.
- 8mo agoPBYIPuma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth
- 8mo agoPBYIPuma Biotechnology to Present at TD Cowen's 46th Annual Health Care ConferenceBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday,
- 9mo agoPBYIPuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial ResultsBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 26, 2026, following the release of its fourth quarter and full year
- 9mo agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on February 3, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit
- 10mo agoPBYINBIPuma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective at the close of trading on Friday, December 19,
- 11mo agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit
- 1y agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit
- 1y agoPBYIPuma Biotechnology Reports Third Quarter 2025 Financial ResultsBusiness WireRaising 2025 NERLYNX® revenue and net income estimates Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2025. Unless
- 1y agoPBYIPuma Biotechnology to Host Conference Call to Discuss Third Quarter Financial ResultsBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, Nov. 6, 2025, following the release of its third quarter 2025 financial
- 1y agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on October 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit
- 1y agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on September 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit
- 1y agoPBYIPuma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 1:00
- 1y agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on August 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit
- 1y agoPBYIPuma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoPBYIPuma Biotechnology Reports Second Quarter Financial ResultsBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2025. Unless otherwise stated, all comparisons are for the second quarter 2025
- 1y agoPBYIPuma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial ResultsBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 7, 2025, following the release of its second quarter 2025 financial
- 1y agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on July 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards
- 1y agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards
- 1y agoPBYIPuma Biotechnology Reports First Quarter Financial ResultsBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025
- 1y agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards
- 1y agoPBYIEr-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer PatientsGlobeNewswireATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it
- 1y agoAZNPBYIPuma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting
- 1y agoPBYIPuma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial ResultsBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 8, 2025, following the release of its first quarter 2025 financial
- 1y agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on April 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards
- 1y agoPBYIPuma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that clinical data on neratinib will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR
- 1y agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit
- 1y agoPBYIPuma Biotechnology to Present at Barclays Annual Global Healthcare ConferenceBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on
- 1y agoPBYIPuma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial ResultsBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth
- 1y agoPBYIPuma Biotechnology to Present at TD Cowen's 45th Annual Health Care ConferenceBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 11:10 a.m. ET on
- 1y agoPBYIPuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial ResultsBusiness WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 27, 2025, following the release of its fourth quarter and full year
- 1y agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit
- 1y agoPBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on January 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit